Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PRTG 
Portage Biotech Inc (PRTG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: PRTG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $140
1 Year Target Price $140
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.36% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.52M USD | Price to earnings Ratio - | 1Y Target Price 140 |
Price to earnings Ratio - | 1Y Target Price 140 | ||
Volume (30-day avg) 1 | Beta 0.64 | 52 Weeks Range 2.95 - 15.82 | Updated Date 10/17/2025 |
52 Weeks Range 2.95 - 15.82 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.72 |
Earnings Date
Report Date 2025-09-25 | When After Market | Estimate - | Actual -2.88 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -92.69% | Return on Equity (TTM) -541.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34113136 | Price to Sales(TTM) - |
Enterprise Value 34113136 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.02 | Shares Outstanding 2278620 | Shares Floating 829851 |
Shares Outstanding 2278620 | Shares Floating 829851 | ||
Percent Insiders 60.57 | Percent Institutions 4.17 |
Upturn AI SWOT
Portage Biotech Inc
Company Overview
History and Background
Portage Biotech Inc. (PRTG) is a clinical-stage immuno-oncology company focused on discovering and developing therapies to improve patient lives and outcomes. Founded to create a portfolio of early-stage assets with the potential to address unmet medical needs in cancer, Portage employs a platform approach to find and develop new immunotherapy drugs and small molecules.
Core Business Areas
- Immuno-Oncology: Portage focuses on developing next-generation therapies that boost the immune system's ability to fight cancer. They achieve this via various strategies that include stimulation of invariant natural killer T (iNKT) cells, inhibition of adenosine production by tumors, and others.
Leadership and Structure
Dr. Ian B Walters is the Chief Executive Officer. The company has a board of directors overseeing strategic decisions. The organizational structure includes departments for research, development, clinical trials, and finance.
Top Products and Market Share
Key Offerings
- PORT-2 (Invariant Natural Killer T (iNKT) cell agonists): PORT-2, which aims to utilize iNKT cells to fight against tumors. It is in early stages of development. Competitors include other companies developing iNKT cell-targeting therapies. Data on market share is not available due to its developmental stage.
- PORT-3 (Adenosine Receptor Antagonist): PORT-3, is an adenosine receptor antagonist designed to block the immunosuppressive effects of adenosine in the tumor microenvironment. Competitors include other pharmaceutical companies developing adenosine receptor antagonists. Data on market share is not available due to its developmental stage.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by advancements in understanding the immune system's role in cancer and the development of novel therapies. The cancer market is highly competitive and continues to grow as the population ages and new diagnostics allow for earlier detection.
Positioning
Portage Biotech is a smaller player in the immuno-oncology field, focused on early-stage development of innovative therapies. Their competitive advantage lies in their platform approach, creating a wide variety of assets that individually carry high risk, but as a portfolio provide a lower overall risk.
Total Addressable Market (TAM)
The global cancer immunotherapy market is estimated to reach several hundred billion USD in the coming years. Portage is positioned to capture a portion of this market with its innovative therapies, but due to their early stage they have not been able to capture the TAM.
Upturn SWOT Analysis
Strengths
- Innovative platform approach
- Experienced management team
- Diverse portfolio of early-stage assets
- Strong intellectual property protection on key assets
Weaknesses
- Limited financial resources compared to larger competitors
- Early-stage pipeline with high clinical development risk
- Dependent on successful clinical trial outcomes
- High Cash Burn.
Opportunities
- Potential for partnerships and collaborations with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Advancement of key assets through clinical trials
- Growing demand for immuno-oncology therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
- AZN
Competitive Landscape
Portage Biotech is a smaller company compared to its competitors and operates within a highly competitive market. It is working on novel solutions with its unique platform approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not readily available.
Future Projections: Future projections are not available.
Recent Initiatives: Portage Biotech Inc is conducting clinical trials of their lead products.
Summary
Portage Biotech is a clinical-stage immuno-oncology company. The company is focusing on novel approaches to stimulating the immune system and is a very small part of the total market. Its key risk is that it is early-stage, so failure rate is higher and funding is difficult to acquire. However, if successful the financial upside could be significant.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Portage Biotech Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.portagebiotech.com |
Full time employees 3 | Website https://www.portagebiotech.com | ||
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.